{
    "organizations": [],
    "uuid": "7257dc3fcf9b28346ac55cbcf290ac0a5a589bcf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/bristol-myers-fda/fda-approves-new-dosing-for-bristol-myers-squibbs-opdivo-idUSL4N1QO43T",
    "ord_in_thread": 0,
    "title": "FDA approves new dosing for Bristol-Myers Squibb's Opdivo",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a new dosing schedule for its drug, Opdivo, across a number of cancers the drug is already approved to treat.\nThe approval was related to a marketing application for an infused 480 mg dose every four weeks.\nOpdivo is already approved to treat a number of cancers such as melanoma. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)\n ",
    "published": "2018-03-06T20:18:00.000+02:00",
    "crawled": "2018-03-07T19:53:48.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "squibb",
        "co",
        "said",
        "tuesday",
        "food",
        "drug",
        "administration",
        "approved",
        "new",
        "dosing",
        "schedule",
        "drug",
        "opdivo",
        "across",
        "number",
        "cancer",
        "drug",
        "already",
        "approved",
        "treat",
        "approval",
        "related",
        "marketing",
        "application",
        "infused",
        "mg",
        "dose",
        "every",
        "four",
        "week",
        "opdivo",
        "already",
        "approved",
        "treat",
        "number",
        "cancer",
        "melanoma",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "maju",
        "samuel"
    ]
}